Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting® 2019
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced it will present preclinical study results on the farnesoid X receptor (FXR) agonist TERN-101 at The Liver Meeting® 2019, being held by the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., November 8-12. The data demonstrate that in preclinical models, TERN-101 was preferentially delivered to the liver, which enables a robust, localized effect on FXR, while potentially mitigating non-liver mediated adverse effects.
The abstract (#2158), titled “Pharmacokinetics, tissue distribution and pharmacodynamics of TERN-101, a novel farnesoid X receptor (FXR) agonist, in preclinical species” will be presented as a poster on Monday, November 11, 2019.
“TERN-101 has the potential to be the backbone of future combination treatments for NASH due to its broad pleiotropic effects of FXR agonism on multiple pathogenetic mechanisms of NASH,” said Erin Quirk, M.D., Chief Medical Officer of Terns. “Our preclinical data show that TERN-101 is efficiently enriched in the liver, the target organ for FXR activity against NASH, which could potentially mitigate non-liver mediated tolerability issues associated with systemic FXR activation.”
TERN-101 has been advanced into clinical studies. A Phase 1 trial demonstrated clinical pharmacokinetic properties consistent with once-daily dosing. At The International Liver Congress™ 2019 in Vienna, Terns presented preclinical data demonstrating that TERN-101 reduced liver steatosis, inflammation, ballooning, and fibrosis in a preclinical model of non-alcoholic steatohepatitis (NASH).
TERN-101 and TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are both in development for the treatment of NASH and were initially discovered and developed by Eli Lilly and Company. Terns signed a global, exclusive agreement with Eli Lilly in 2018 to develop, manufacture, and commercialize TERN-101, TERN-201, and another preclinical candidate that inhibits an undisclosed NASH target.
About TERN-101 and Farnesoid X Receptor (FXR) Agonism
TERN-101 is a potent non-bile acid FXR agonist being developed as a therapeutic for NASH. FXR is a nuclear receptor that is highly expressed in the liver and small intestine. Bile acids (BA) are natural ligands of FXR, and their binding with and activation of FXR is critical to the regulation of cellular pathways that modulate BA synthesis, lipid metabolism, inflammation, and fibrosis. FXR agonism and activation has demonstrated improvement over placebo in regression of histological liver fibrosis without progression to NASH in a late-stage study, demonstrating the potential for FXR agonists to be a new treatment modality for NAFLD and NASH.
About NASH
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), which is caused by the accumulation of excess fat in the liver. NASH is associated with chronic liver inflammation and liver cell injury, and it can lead to fibrosis, cirrhosis, and eventually liver cancer or liver failure. Global rates of NAFLD and NASH are increasing rapidly, in tandem with rising rates of obesity. There is currently no approved medication for the treatment of NASH.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer. Based in China and the United States, the company is advancing a pipeline of drug candidates for the treatment of non-alcoholic steatohepatitis (NASH) and cancer, across multiple modalities. Terns leverages world class expertise in disease biology, medicinal chemistry, and clinical development in order to bring promising new therapies to patients in China and other global markets.
For more information, visit www.ternspharma.com and www.ternspharma.com.cn
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005032/en/
Contact information
US Media Contact:
Margaret Robinson
+1 (415) 690 0084
China Media Contact:
Zhou Zhou
+86 13482103703
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Panasonic and KOSÉ Set to Commence Verification Test for Personalized Proposals Utilizing Snow Beauty Mirror6.12.2019 05:37:00 EET | Press release
Panasonic Corporation is collaborating with KOSÉ Corporation to conduct a joint verification test using Snow Beauty Mirror, a system under development by Panasonic, with the aim of offering personalized proposals at Maison KOSÉ, a store which is due to open on December 17. Through this initiative, Panasonic will help make new personalized proposals that meet the diverse needs of its customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005971/en/ Snow Beauty Mirror (Displays the results of skin analysis covering five categories) (Photo: Business Wire) People’s values and lifestyles are becoming increasingly diverse. In today’s world, everyone requires something different from their cosmetics. Meanwhile, customers are confronted with a deluge of information through the Internet and social media, which sometimes makes it difficult for them to select cosmetics that really suit their needs. A solution to this conundrum
Citi Private Bank Issues Outlook 2020: Global Growth Can Endure Over the Coming Year5.12.2019 21:30:00 EET | Press release
Citi Private Bank today released its Outlook report for 2020, titled, “Staying Positive in a Negative (Yielding) World.” The twice-yearly publication provides in-depth insights into the global economy and financial markets for the coming year, and highlights important multi-year investment themes for client portfolios. The report highlights Citi Private Bank’s view that global economic growth can endure through 2020 given expectations that corporate earnings will continue to grow at a solid pace; global equities may continue to rise higher; and with global fixed income yields at record lows, they anticipate the sector will continue to struggle in 2020. “The year ahead promises to be an eventful year for investors,” said David Bailin, Chief Investment Officer, Citi Private Bank. “Our Outlook 2020 cuts through the noise and focuses on what really matters for our clients’ wealth and provides sector recommendations to potentially enhance total return profiles.” He continued, “We believe gl
Kanguru Leaps Over The Competition With A New OS Agnostic Encrypted Fingerprint Access Flash Drive5.12.2019 19:31:00 EET | Press release
Kanguru is proud to announce the launch of the world’s first OS Agnostic, Fingerprint Access Hardware Encrypted Flash Drive with remote management capability. This new biometric fingerprint access flash drive supplants the bulky pinpads and fussy combo keypads of leading encrypted devices, making it much more convenient and easy to use. With just a tap of the finger, the new Kanguru Defender Bio-Elite30™ Fingerprint Hardware Encrypted Flash Drive provides quick access to encrypted files. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005662/en/ The New Kanguru Defender Bio-Elite30 Fingerprint Hardware Encrypted Flash Drive is OS Agnostic, remotely manageable, and provides best-in-class encryption with easy fingerprint access! (Photo: Business Wire) Being OS Agnostic, the Defender Bio-Elite30 can be used on virtually any machine, from Windows and MacOS, to medical equipment, smart TVs and even ATMs for making bank machi
Sensor Electronic Technology Obtains Permanent Injunction Against U.S. UV LED Companies5.12.2019 17:00:00 EET | Press release
Sensor Electronic Technology, Inc. (“SETi”), a leading global innovator of deep UV LED products and technology, announced that it successfully obtained a permanent injunction in a patent infringement lawsuit against Bolb, Inc. (“Bolb”), and Quantum Egg, Inc. (“Q-Egg”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005031/en/ The history of UV LED business (Graphic: Business Wire) The California Northern District federal court issued a permanent injunction against the sales of an accused UV LED sterilizer device, as well as any mere colorable variations, according to the parties’ stipulation. The Court will therefore prohibit the sale of similar products if they prove to be mere colorable variations of the accused products. The asserted patents in this litigation cover fundamental UV LED technology, encompassing UV LED sterilizer structures and drivers, chip fabrication, and epitaxial layer growth. Bolb is a UV LED com
SHRM--Society for Human Resource Management and Prometric Renew Long-Term Partnership with Multi-year Agreement5.12.2019 17:00:00 EET | Press release
Following a comprehensive procurement process, we’re excited to announce that SHRM--Society for Human Resource Management®, the voice of all things work, has selected Prometric® as its strategic testing partner. Under the renewal, Prometric will assist in the delivery of the SHRM Certified Professional (SHRM-CP®) and SHRM Senior Certified Professional (SHRM-SCP®) exam programs—the global certification standard for the HR profession. This agreement extends the partnership between the organizations that started in 2010. Since inception of the certification program in 2014, Prometric has partnered with SHRM to deliver more than 75,000 exams globally with over 90% growth since the first administration. With businesses increasingly recognizing that effective people management is a strategic imperative, leaders now expect HR professionals to also demonstrate the behavioral competencies required to effectively apply knowledge in the modern workplace. By incorporating key HR competencies and k
Sartorius Acquires a Majority Stake in Cell Culture Media Specialist Biological Industries5.12.2019 16:19:00 EET | Press release
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, signed an agreement to acquire a majority stake in the Israeli cell culture media developer and manufacturer Biological Industries. For approximately €45 million in cash, Sartorius is acquiring just over 50% of the shares of the company from its owners, Kibbutz Beit Haemek and private equity fund Fortissimo Capital. An option to acquire a further 20% of the shares within three years was also agreed. The transaction is subject to customary closing conditions and expected to be finalized by mid-December. “By acquiring a majority stake in Biological Industries, we are significantly expanding our cell culture media offering and complementing our product portfolio for customers in the dynamically growing advanced therapies market,” commented Joachim Kreuzburg, CEO of the Sartorius Group. Biological Industries focuses on cell culture media, particularly for cell and gene therapy, regenerat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom